Reveal Genomics HER2DX Assay to Be Prospectively Evaluated in ECOG-ACRIN Trial | Precision Medicine Online REVEAL GENOMICS

shorturl.at/iLSUX #COI

🎉👏ESMO Breast 2024 ESMO - Eur. Oncology

Excited to announce that our medical oncologist, Dr. Tomás Pascual, will be co-presenting an educational talk alongside Sara Tolaney and Tatiana Prowell, MD

👇👇👇
Unlocking the potential of biomarker-based trial designs in advancing new therapeutics (ID…

🎉👏Delighted to announce that our team has secured 2 out of the 20 ESMO Merit Travel Grants for the ESMO Breast Cancer 2024 conference! ESMO - Eur. Oncology

Guillermo Villacampa
1MO - HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with…

Just out 🚨on eBioMedicine – The Lancet Discovery Science
Study explores the potential of a B-cell/immunoglobulin signature (IGG), alone or combined with tumor burden, to predict prognosis and treatment response in early-stage triple-negative #BreastCancer

➡️ indicating its promise in guiding personalized…

🎯 B-cell/immunoglobulin signature (IGG) was associated with improved EFS (HR = 0.77) and OS (HR = 0.79) across 7 cohorts of early stage TNBC

🕵🏼‍♀️IGG + clinical features could help identifying pts benefitting from intensified or de-intensified tp
👏🏻 🤩Benedetta Conte
OncoAlert

Very happy to see that our paper on eBioMedicine – The Lancet Discovery Science is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️Aleix Prat #PrecisionOncology EVOMET Fara Brasó Maristany

Our new article is out, led by Olga Martínez-Sáez!

Management of early-stage HER2+ breast cancer and attitudes towards HER2DX in Spain

An online questionnaire was conducted by an independent third-party across 70 medical oncologists highly specialized in breast cancer in Spain…

👇Check this new article from our own Benedetta Conte Aleix Prat #PrecisionOncology and Fara Brasó Maristany 👏👏👏

Dr. Nancy Lin's #DESTINYBreast12 trial on #TrastuzumabDeruxtecan , an antibody drug conjugate
used for #BrainMetastasis treatment, was listed by Nature Medicine as one of the likely trials to have an outsized impact on medicine in 2024.
nature.com/articles/s4159…
Nancy Lin, MD #ADCs #TDXd